Biomarin Pharmaceutical (BMRN)

Add to Watchlists
Create an Alert
60.89 -0.48  -0.78% NASDAQ Apr 17, 8:00PM BATS Real time Currency in USD

Biomarin Pharmaceutical Research and Development Expense (Quarterly):

97.31M for Dec. 31, 2013

View 4,000+ financial data types

View Full Chart

Biomarin Pharmaceutical Research and Development Expense (Quarterly) Chart

Export Data
Save Image

Biomarin Pharmaceutical Historical Research and Development Expense (Quarterly) Data

Export Data Date Range:
Viewing of   First  Previous First  Previous   Next  Last Next   Last
Data for this Date Range  
Dec. 31, 2013 97.31M
Sept. 30, 2013 88.06M
June 30, 2013 85.66M
March 31, 2013 83.74M
Dec. 31, 2012 84.36M
Sept. 30, 2012 66.21M
June 30, 2012 77.81M
March 31, 2012 73.83M
Dec. 31, 2011 57.91M
Sept. 30, 2011 58.58M
June 30, 2011 52.91M
March 31, 2011 45.02M
Dec. 31, 2010 42.20M
Sept. 30, 2010 39.37M
June 30, 2010 35.65M
March 31, 2010 30.10M
Dec. 31, 2009 27.44M
Sept. 30, 2009 26.99M
June 30, 2009 26.32M
March 31, 2009 Upgrade
Dec. 31, 2008 Upgrade
Sept. 30, 2008 Upgrade
June 30, 2008 Upgrade
March 31, 2008 Upgrade
Dec. 31, 2007 Upgrade
   
Sept. 30, 2007 Upgrade
June 30, 2007 Upgrade
March 31, 2007 Upgrade
Dec. 31, 2006 Upgrade
Sept. 30, 2006 Upgrade
June 30, 2006 Upgrade
March 31, 2006 Upgrade
Dec. 31, 2005 Upgrade
Sept. 30, 2005 Upgrade
June 30, 2005 Upgrade
March 31, 2005 Upgrade
Dec. 31, 2004 Upgrade
Sept. 30, 2004 Upgrade
June 30, 2004 Upgrade
March 31, 2004 Upgrade
Dec. 31, 2003 Upgrade
Sept. 30, 2003 Upgrade
June 30, 2003 Upgrade
March 31, 2003 Upgrade
Dec. 31, 2002 Upgrade
Sept. 30, 2002 Upgrade
June 30, 2002 Upgrade
March 31, 2002 Upgrade
Dec. 31, 2001 Upgrade
Sept. 30, 2001 Upgrade

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More

Get data for
Advertisement

BMRN Research and Development Expense (Quarterly) Benchmarks

Companies
Alexion Pharmaceuticals 85.78M
Regeneron Pharmaceuticals 268.14M
Sangamo BioSciences 10.78M

BMRN Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 26.32M Jun 2009
Maximum 97.31M Dec 2013
Average 57.87M
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.